BTIG analyst David Larsen initiated coverage of Definitive Healthcare with a Buy rating and $7 price target. Definitive is one of the healthcare industry’s most comprehensive data collection and analytics platforms that supports biopharma, life sciences, health systems, med-tech, and the broad healthcare ecosystem, the analyst tells investors in a research note. The firm says that while the stock has come under pressure over the past three years, biopharma research and development and the company’s revenue growth “are starting to pick back up.” BTIG likes how fund raising efforts are improving for biotech, and notes the Centers for Medicare and Medicaid Services wants the vast majority of Medicare members in value-based or risk deals by 2030.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DH:
- Definitive Healthcare to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
- Definitive Healthcare launches powerful consumer analytics and activation solution to more industries with Population Intelligence expansion
- Definitive Healthcare expands Population Intelligence platform
- Definitive Healthcare price target lowered to $5 from $7 at Deutsche Bank
- Definitive Healthcare price target lowered to $5 from $6 at Baird